Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Weekly Report Card

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jul 12, 2021 4:50pm

137 Views

Post# 33531049

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Weekly Report Card

It's amazing how hard some try to justify the low valuation from the science advisors are Canadian to high risks of "preclinical" programs.
If that's the attitude of the market this company will never will be valued fairly cause all the cons not pros will be a hindrance regardless if they are phase 1,2.3 oncology or NASH phase 3 company. This is the perception atm and this is the challenge this company has to deal with, it won't go away until it's death with. Folks believe marketing has nothing to do with the valuation if correct they should close the IR department stop spending on marketing altogether. How is that for plan??

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks